Amgen grants 730 RSUs to finance executive Busch

Busch Matthew C. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Busch Matthew C. reported acquisition or exercise transactions in this Form 4 filing.

Amgen Inc. reported that officer Matthew C. Busch, VP, Finance & CAO, received an equity compensation award of 730 shares of Common Stock in the form of Restricted Stock Units (RSUs) on 2026-08-07. The RSUs were granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vest in four equal annual installments of 25%, beginning on 8/7/2027. Vested RSUs will be settled in shares of Amgen common stock on a one-to-one basis. Following this award, Busch holds 5,080 shares directly, which include 45 Dividend Equivalents (DEs) credited to his unvested RSUs.

Insider Trade Summary

Grant/Award: 730 shares

Grant/Award 1 txn

Insider Busch Matthew C.

Role VP, Finance & CAO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	730	$0.00	$0.00

Holdings After Transaction: Common Stock — 5,080 shares (Direct)

Footnotes (2)

1. F1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 8/7/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
2. F2. These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Key Figures

RSU shares granted: 730 shares Post-award holdings: 5,080 shares Dividend Equivalents included: 45 DEs +2 more

5 metrics

RSU shares granted 730 shares Restricted Stock Units granted on 2026-08-07 as equity award

Post-award holdings 5,080 shares Total Amgen common shares directly held by Matthew C. Busch after transaction

Dividend Equivalents included 45 DEs DEs credited to unvested RSUs and included in reported share total

Vesting schedule 25% annually over four years RSUs vest in four equal annual installments starting 8/7/2027

Vesting commencement date 8/7/2027 Date first 25% installment of RSUs is scheduled to vest

Key Terms

Restricted Stock Units (RSUs), Dividend Equivalents (DEs), Equity Incentive Plan, qualifying dividend reinvestment plan

4 terms

Restricted Stock Units (RSUs) financial

"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended..."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Dividend Equivalents (DEs) financial

"These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan..."

Equity Incentive Plan financial

"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan..."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

qualifying dividend reinvestment plan financial

"DEs granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did Amgen (AMGN) grant to Matthew C. Busch?

Amgen granted 730 RSU-based Common Stock shares to Matthew C. Busch on 2026-08-07 under its Equity Incentive Plan. The RSUs vest in four equal 25% annual installments starting 8/7/2027 and are settled in Amgen common stock.

How do the new RSUs for Amgen (AMGN) executive Matthew C. Busch vest?

The RSUs vest in four equal annual installments of 25%, beginning on 8/7/2027. Each vested portion will be paid out in Amgen common stock on a one-to-one basis, aligning the executive’s compensation with share performance over time.

What are Matthew C. Busch’s total Amgen (AMGN) share holdings after this Form 4?

After the reported award, Matthew C. Busch directly holds 5,080 shares of Amgen common stock. This total includes 45 Dividend Equivalents (DEs) that are credited to his unvested RSUs and will pay out in shares as the RSUs vest.

What are Dividend Equivalents (DEs) in the Amgen (AMGN) Form 4 for Matthew C. Busch?

The filing notes 45 Dividend Equivalents (DEs) credited to Busch’s unvested RSUs under a qualifying dividend reinvestment plan. These DEs are paid in Amgen common stock on a one-to-one basis as the RSUs vest, plus cash for any fractional share amounts.

Under which plan were Matthew C. Busch’s Amgen (AMGN) RSUs granted?

The RSUs were granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. This plan provides equity-based awards like Restricted Stock Units (RSUs) and related Dividend Equivalents (DEs) to align management incentives with shareholder interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 08:05 PM Accepted by SEC EDGAR 08/12/2026 - 08:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Busch Matthew C.

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Finance & CAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2026		A		730(1)	A	$0	5,080(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 8/7/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

2. These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Matthew C. Busch	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)